Jo CE - Search Results

1

Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].

Jo CE, Georgakopoulos JR, Ladda M, Ighani A, Mufti A, Drucker AM, Piguet V, Yeung J. Jo CE, et al. J Cutan Med Surg. 2020 Sep/Oct;24(5):468-473. doi: 10.1177/1203475420928907. Epub 2020 May 22. J Cutan Med Surg. 2020. PMID: 32442020

2

Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study.

Jo CE, Georgakopoulos JR, Ladda M, Ighani A, Mufti A, Drucker AM, Piguet V, Yeung J. Jo CE, et al. J Am Acad Dermatol. 2020 Jun;82(6):1530-1532. doi: 10.1016/j.jaad.2020.02.029. Epub 2020 Feb 16. J Am Acad Dermatol. 2020. PMID: 32074486 No abstract available.

3

Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use.

Jo CE, Georgakopoulos JR, Drucker AM, Piguet V, Yeung J. Jo CE, et al. J Cutan Med Surg. 2020 Sep/Oct;24(5):527-528. doi: 10.1177/1203475420929920. Epub 2020 May 25. J Cutan Med Surg. 2020. PMID: 32449620 No abstract available.

4

Facial and neck erythema associated with dupilumab treatment: A systematic review.

Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Jo CE, et al. J Am Acad Dermatol. 2021 May;84(5):1339-1347. doi: 10.1016/j.jaad.2021.01.012. Epub 2021 Jan 8. J Am Acad Dermatol. 2021. PMID: 33428978

5

Effect of dupilumab on allergic contact dermatitis and patch testing.

Jo CE, Mufti A, Sachdeva M, Pratt M, Yeung J. Jo CE, et al. J Am Acad Dermatol. 2021 Jun;84(6):1772-1776. doi: 10.1016/j.jaad.2021.02.044. Epub 2021 Feb 19. J Am Acad Dermatol. 2021. PMID: 33617912 No abstract available.

6

Prevalence and Characteristics of Dupilumab-Induced Ocular Surface Disease in Adults With Atopic Dermatitis.

Felfeli T, Georgakopoulos JR, Jo CE, Mimouni M, Piguet V, Drucker AM, Yeung J, Chan CC. Felfeli T, et al. Among authors: jo ce. Cornea. 2022 Oct 1;41(10):1242-1247. doi: 10.1097/ICO.0000000000002866. Epub 2021 Oct 19. Cornea. 2022. PMID: 34843182

7

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study.

Georgakopoulos JR, Felfeli T, Drucker AM, Jo CE, Piguet V, Yeung J. Georgakopoulos JR, et al. Among authors: jo ce. JAAD Int. 2021 Jul 31;4:67-69. doi: 10.1016/j.jdin.2021.06.001. eCollection 2021 Sep. JAAD Int. 2021. PMID: 34409396 Free PMC article. No abstract available.

8

Topical treatment for postinflammatory hyperpigmentation: a systematic review.

Tan MG, Kim WB, Jo CE, Nabieva K, Kirshen C, Ortiz AE. Tan MG, et al. Among authors: jo ce. J Dermatolog Treat. 2022 Aug;33(5):2518-2526. doi: 10.1080/09546634.2021.1981814. Epub 2021 Sep 27. J Dermatolog Treat. 2022. PMID: 34525885 Free article.

9

TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors.

Jo CE, Gooderham M, Beecker J. Jo CE, et al. Int J Dermatol. 2022 Feb;61(2):139-147. doi: 10.1111/ijd.15605. Epub 2021 Apr 30. Int J Dermatol. 2022. PMID: 33929045 Review.

10

Availability and quality of patient decision aids for dermatologic conditions.

Jo CE, Lee A, Finstad A, Kirshen C. Jo CE, et al. J Am Acad Dermatol. 2021 Nov;85(5):1304-1306. doi: 10.1016/j.jaad.2020.08.115. Epub 2020 Sep 4. J Am Acad Dermatol. 2021. PMID: 32891784 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters